Loading
Royalty Pharma plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Jun 2023.
Royalty Pharma plc: what insiders have been doing
Royalty Pharma plc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 70 filings came from 14 insiders.
The flow runs one way only: 38 sales worth €52.6M, from 5 insiders, and no purchase. No amount is published for 2 filings, which the totals therefore leave out. At €5.2M, the sale published on 19 August 2026 by Hite Christopher is the largest of the period (0.017% of market cap).
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 70 filings here. Since 2021, the database holds 5 purchases and 107 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 2.38 bn USD and net income at 770.9 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
254
Thresholds
n/a
Buy Volume
€15M
5 ops. · all time
Sell Volume
€301M
107 ops. · all time
Who traded when
BuySaleTerrance P. Coyne17 sales
Marshall Urist13 sales
Christopher Hite5 sales
Lloyd George W.3 sales
Norden Gregory1 sale
Since the insiders bought
- -13.8%Entry US$30.58 · Close at T+365 US$26.37
- -8.0%Entry US$39.26 · Close at T+365 US$36.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Royalty Pharma plc Strong Buy (bullish), based on 8 analysts. Average price target: US$65.38.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,316 of 24,148 companies
53.2
score / 100
Value45
Quality62
FCF yld7.2%
Earn yld2.2%
EV/EBITDA26.5x
ROE14%
Gross mgn·
Net mgn32%
Debt/EBITDA5.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$56.57
Analyst consensus
8 analystsStrong buy
US$61.00Target US$65.38(+16%)US$70.00
Income statement
RevenueUS$2.4B
EBITDAUS$1.6B69% margin
Net incomeUS$770.9M32.0% margin
Valuation
PER (trailing)30.1x
PER (forward)9.8x
P/Book3.7x
Beta0.41
Balance sheet & cash
Market capUS$32.7B
Total debtUS$9B
Free Cash FlowUS$2.5B
Debt / Equity92%
Profitability & ownership
ROE14.0%
ROA5.1%
% insiders6.5%
% institutions87.7%
Last declaration on 5 October 2026
Declarations254 total
4,126 shares@ US$57.100.0007% mcap1.6% of flowClass A Ordinary SharesSEC:0001838139-26-000028:0
642 shares@ US$58.40550.0001% mcap4.6% of flowClass A Ordinary SharesSEC:0001683607-26-000016:0
4,126 shares@ US$57.880.0007% mcap1.7% of flowCommon StockSEC144:0001964306-26-000456
96,073 shares@ US$58.51480.016% mcap47.7% of flowClass A Ordinary SharesSEC:0001814238-26-000017:0
3,927 shares@ US$58.92610.0007% mcap2.0% of flowClass A Ordinary SharesSEC:0001814238-26-000017:1
100,000 shares@ US$58.46970.017% mcap22.7% of flowClass A Ordinary SharesSEC144:0001628280-26-063061
16,800 shares0Class A Ordinary SharesSEC:0001814238-26-000015:1
100,000 shares@ US$59.97250.017% mcap50.4% of flowClass A Ordinary SharesSEC:0001814238-26-000015:0
100,000 shares@ US$60.120.017% mcap23.1% of flowClass A Ordinary SharesSEC144:0001628280-26-057721
9,230 shares@ US$58.58640.0016% mcap1.5% of flowClass A Ordinary SharesSEC:0001814876-26-000027:0
1,772 shares@ US$59.14150.0003% mcap0.3% of flowClass A Ordinary SharesSEC:0001814876-26-000027:1
11,002 shares@ US$58.560.0019% mcap100.0% of flowCommon StockSEC144:0001958244-26-000508
125,000 shares@ US$57.790.021% mcap37.7% of flowClass A ordinary sharesSEC144:0001968582-26-000827
206,352 shares@ US$57.790.035% mcap62.3% of flowClass A ordinary sharesSEC144:0001968582-26-000828
11,002 shares0Class A Ordinary SharesSEC:0001814876-26-000025:0
65,216 shares0Class A Ordinary SharesSEC:0001507678-26-000006:0
8,252 shares0Class A Ordinary SharesSEC:0001838139-26-000024:0
11,002 shares0Class A Ordinary SharesSEC:0001814238-26-000013:0
100,000 shares@ US$57.090.017% mcap22.3% of flowClass A Ordinary SharesSEC144:0001628280-26-046352
9,099 shares@ US$55.88020.0015% mcap3.6% of flowCommon StockSEC144:0001964306-26-000306
689 sharesClass A Ordinary SharesSEC:0001683607-26-000014:0
32,408 sharesClass A Ordinary SharesSEC:0001814238-26-000009:0
117,592 sharesClass A Ordinary SharesSEC:0001814238-26-000009:1
9,098 shares@ US$55.18430.0016% mcap3.5% of flowCommon StockSEC144:0001964306-26-000296
30,000 shares@ US$55.350.0051% mcap100.0% of flowClass A Ordinary SharesSEC144:0001628280-26-044949
25 of 254 declarations
About Royalty Pharma plc
Royalty Pharma plc is a leading buyer and manager of biopharmaceutical royalty streams, listed on the U.S. Nasdaq under ticker RPRX in the United States. For French-, Belgian- and Swiss-based investors, the company is best understood not as a traditional drug developer but as a specialist capital provider to the life sciences industry. It finances biotech and pharma companies in exchange for royalties, synthetic royalties, and other structured economics tied to future product sales. The company is headquartered in New York, placing it at the center of the U.S. healthcare and capital-markets ecosystem.
Founded in the late 1990s by Pablo Legorreta, Royalty Pharma built its franchise around a simple but powerful idea: pharmaceutical innovation can be financed through royalty monetization. Over time, this evolved from a niche strategy into a large-scale institutional platform. The company has expanded from buying royalties on marketed drugs to structuring bespoke funding transactions across development-stage and commercial assets. This evolution has helped Royalty Pharma become one of the most recognized names in the biopharma royalty market.
Read moreShow less
Its core business lines include the acquisition of existing royalties on approved products, the provision of R&D financing in exchange for future royalty rights, and the management of a diversified portfolio of therapeutic assets. Royalty Pharma’s exposure spans multiple disease areas, including oncology, rare diseases, immunology, respiratory disorders, and neurology. This breadth matters strategically: it reduces single-asset concentration risk while creating optionality across different stages of the drug development and commercialization cycle.
From a competitive standpoint, Royalty Pharma holds a strong position due to its scale, transaction expertise, and long-standing relationships with biopharma companies. It is often viewed as a preferred partner for companies seeking non-dilutive funding. The group’s investment approach requires deep scientific, regulatory, and commercial analysis, because royalty economics depend on the long-term success of individual products. That analytical capability is one of its key differentiators versus generalist capital providers.
Recent developments have reinforced the company’s active capital-allocation strategy. In 2025, Royalty Pharma announced major transactions including a $2 billion funding arrangement with Revolution Medicines, a $275 million royalty funding agreement with Denali Therapeutics, and the acquisition of a royalty interest in Amgen’s Imdelltra. The company also reported strong 2025 results and positive 2026 guidance, underscoring the resilience of its cash-generating model. For investors, RPRX offers a distinctive combination of healthcare exposure, contract-based cash flows, and structured-finance characteristics within the U.S. listed market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
